Type 2 Diabetes and Developmental Origin of Non-Alcohol Fatty Liver Disease and Future Directions of TreatmentEl-Sayyad HI1* and El-Shahary EA2
- *Corresponding Author:
- El-Sayyad HI
Department of Zoology, Faculty of Science
Mansoura University, Mansoura, Egypt
E-mail: [email protected]
Received Date: September 19, 2016; Accepted Date: September 29, 2016; Published Date: October 06, 2016
Citation: El-Sayyad HI, El-Shahary EA (2016) Type 2 Diabetes and Developmental Origin of Non-Alcohol Fatty Liver Disease and Future Directions of Treatment. Clin Exp Pharmacol 6:220. doi:10.4172/2161-1459.1000220
Copyright: © 2016 El-Sayyad HI, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Non-alcohol fatty liver disease is a large public health problem developed earlier during intrauterine life as a result of gestational or type 2 diabetes. The disease is associated with altered liver enzymes, lipid accumulation and hepatic steatosis due to hepatic de novo lipogenesis. Multiple factors are associated in the development of the disease such as peroxisome proliferator-activated receptor-γ co-activator, B-cell dysfunction and abnormal metabolism of mitochondria, lysosomes, rough endoplasmic reticulum and Golgi complex. These factors are discussed in details. Different approaches of drug-treatment, phyto-& gene therapy are illustrated. Role of type 2 or gestational diabetes on developmental origin of fatty liver. The interrelation-ship between type 2 diabetes and obesity and fetus's liver. Role of cytoplasmic organelles in de novo lipogenesis, inflammation, and hepatocyte cell death. Future direction of drug-treatment, phyto-and gene-therapy.